Tag Archives: DEA

Student Detained 5 Days Without Food Or Water By DEA Settles For $4.1M

By Robert W. Wood, Contributor

Daniel Chong, a 25-year old UC San Diego student, settled his suit against the DEA for $4.1M. He was jailed and left unmonitored in a cell for five days. Chong and eight others were detained April 21, 2012 after DEA agents raided a house in San Diego. The feds seized ecstasy, marijuana, prescription medications, hallucinogenic mushrooms, guns and ammunition. See Daniel Chong, forgotten in DEA cell, settles suit for $4.1 million. …read more

Source: FULL ARTICLE at Forbes Latest

6 Colombian nationals indicted for kidnapping and murder of DEA agent

Six Colombian nationals were indicted by a federal grand jury Thursday for the kidnapping and murder of a U.S. Drug Enforcement Administration agent. A seventh Colombian was charged with trying to destroy evidence in the case.

The indictment alleges that DEA agent Terry Watson was slain at the hands of an organized group of robbers who operated taxi cabs in Bogota, Colombia in order to lure victims whom they perceived as wealthy.

The defendants, who are all under arrest in Colombia, targeted Watson for what the defendants called a “millionaire’s ride,” says the indictment.

Watson was working for the U.S. Mission in Colombia when he entered a taxi cab on June 20 operated by one of the defendants and was then allegedly attacked by two other defendants — one who used a stun gun on Watson and another who stabbed Watson with a knife.

Watson was able to escape, but he soon collapsed and was brought to a hospital, where he died from multiple stab wounds.

The indictment was handed up in federal court in Alexandria, Va.

The defendants are Gerardo Figueroa Sepulveda, 38; Omar Fabian Valdes Gualtero, 27; Edgar Javier Bello Murillo, 26; Hector Leonardo Lopez, 23; Julio Estiven Gracia Ramierez, 30; and Andrés Alvaro Oviedo-Garcia, 21. Each was charged with two counts of second-degree murder, one count of kidnapping and one count of conspiracy to kidnap. Oviedo-Garcia was also charged with two counts of assault. In addition, the grand jury indicted Wilson Daniel Peralta-Bocachica, 30, also a Colombian national, for allegedly trying to destroy evidence associated with the murder.

A Justice Department official declined comment on the question of extraditing the seven to the U.S.

…read more

Source: FULL ARTICLE at Fox US News

White House Budget Would Fund Drug Punishment Over Treatment

By The Huffington Post News Editors

WASHINGTON — The Obama administration budget released Wednesday emphasizes drug abuse punishment and interdiction over treatment and prevention, despite recent rhetoric from the Office of National Drug Control Policy on a “21st century” approach.

The White House budget proposal for fiscal 2014 devotes 58 percent of drug-control spending to punishment and interdiction, compared with 42 percent to treatment and prevention. The drug control spending ratio in this year’s budget is even more lopsided, 62 percent to 38 percent.

“The administration deserves some credit for moving this ratio slightly in the right direction over the years, but a drug control budget that increases funding for the DEA and the Bureau of Prisons is simply not the kind of strategy we need in the 21st century,” said Marijuana Majority spokesman Tom Angell. “At a time when a majority of Americans support legalizing marijuana, and states are moving to end prohibition, this president should be spending less of our money paying narcs to send people to prison, not more. If, as administration officials say, ‘We can’t arrest our way out of the drug problem,’ then why are they continuing to devote so many resources to arresting people for drug problems?”

Read More…
More on Obama’s Budget

Source: FULL ARTICLE at Huffington Post

The Role Medication Plays in Treating Obesity

By Max Macaluso, Ph.D., The Motley Fool

Filed under:

Last summer, the Food and Drug Administration approved two new medications for the treatment of obesity. VIVUS‘ Qsymia has already reached the market, while Arena Pharmaceuticals  Belviq will be launched by its commercialization partner Eisai once the drug clears DEA scheduling. A third player, Orexigen Therapeutics , is still developing its drug Contrave. The fact that obesity affects more than a third of American adults today has attracted many biotech investors to these stocks, but many may not fully understand how physicians approach treatment for this disease. For instance, are exercise and diet all patients really need to manage their weight?

To help clarify this complex topic, Motley Fool health-care analyst Max Macaluso spoke with Dr. Domenica Rubino, a weight-management expert and representative of The Obesity Society. In the following segment from their discussion, Dr. Rubino discusses the role that drugs play in treating obesity. A transcript follows the video.

What macro trend was Warren Buffett referring to when he said “this is the tapeworm that’s eating at American competitiveness”? Find out in our free report: “What’s Really Eating at America’s Competitiveness.” You’ll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.

The relevant video segment can be found between 5:20 and 8:17.

Max Macaluso: Let’s pivot the discussion to drugs and treatment now. Arena recently got Belviq approved. It’s not on the market yet. Vivus got Qsymia approved, and Orexigen is still developing Contrave. What role do drugs really play in treatment?

Dr. Domenica Rubino: A fundamental thing to understand is that the physiology of obesity is actually very complicated. Just as I was saying there are multiple causes of obesity, there are multiple factors that protect weight.

What people don’t really understand is that the body is totally focused on holding onto weight, at all costs. People like to say, “Well, you just eat less, move more.” It’s not as simple as that, because when we do lose weight — and countless people who struggle with this lose weight — there are a lot of mechanisms that kick in.

There are endocrine signals coming from the fat cells, muscle cells, the GI tract, all to the brain to say, “Hold onto that weight.”

What happens to that person is they get hungrier, they don’t really want to move, certain foods look much more appealing, certain parts of the brain are lighting up, thinking, “Oh, I want that.”

What else can happen is that people start to lose their sense of portion. The same subject, before weight loss and after weight loss, will not be able to estimate that portion anymore. Your body is in full-court press to regain weight.

That’s where these medications can be really helpful. They augment our toolbox, as physicians, because primarily what we work with is helping people make lifestyle changes, identifying those factors that I was talking about.

Do they have sleep apnea? …read more

Source: FULL ARTICLE at DailyFinance

Is This Obesity-Drug Maker in Trouble?

By Max Macaluso, Ph.D., The Motley Fool

Filed under:

With Arena Pharmaceuticals  and Eisai still waiting for their obesity drug Belviq to complete DEA scheduling, it was their chief rival VIVUS that made news today. All eyes were on VIVUS‘ decision to take out a loan that could amount to $110 million.

But why is this necessary at all? Does the company need more capital to enhance its marketing strategy for the obesity drug Qsymia, or is this a signal that VIVUS is currently in a difficult financial situation? Health-care analyst Max Macaluso sheds light on this news in the following video.

Is now the time to sell VIVUS?
VIVUS‘ shares were clobbered after Qsymia’s dismal launch. Investors everywhere are wondering whether the tide will turn for this fledgling drugmaker or if now is the perfect time to sell. In a new premium research report, the Fool’s top health-care contributor breaks down this complex story and explains the details VIVUS investors must know — including reasons to buy and sell. To find out more about this premium report click here now.

var FoolAnalyticsData = FoolAnalyticsData || []; FoolAnalyticsData.push({ eventType: “TickerReportPitch”, contentByline: “Max Macaluso, Ph.D.”, contentId: “cms.27444”, contentTickers: “NASDAQ:ARNA, NASDAQ:VVUS”, contentTitle: “Is This Obesity-Drug Maker in Trouble?”, hasVideo: “True”, pitchId: “58”, …read more
Source: FULL ARTICLE at DailyFinance

Medical Marijuana Reformers Ask D.C. Circuit Court For Another Hearing

By The Huffington Post News Editors

NEW YORK — A medical marijuana group filed a petition on Friday with the US Court of Appeals for the District of Columbia Circuit, asking for do-over on a key ruling in the fight to reclassify the drug as safe for medical use.

As Americans for Safe Access acknowledged in its court filing, such re-hearings are “extraordinary and rarely granted.” That means the next stop in the long-running battle against the Drug Enforcement Agency could be the Supreme Court, setting up a high court battle over patients’ right to get high.

In January the D.C. Circuit held that Michael Krawitz, an Air Force veteran denied access to Veterans Administration benefits because he wanted to be able to use medical marijuana, could sue the DEA over its failure to reschedule marijuana as a drug that does have some medical uses.

Read More…
More on Medical Marijuana

…read more
Source: FULL ARTICLE at Huffington Post

Will This Obesity Biotech's Latest Scheme Boost Sales?

By Max Macaluso, Ph.D., The Motley Fool

Filed under:

Drugmaker VIVUS has struggled to ramp up sales of its recently approved obesity medication Qsymia. With competition from Arena Pharmaceuticals  and its partner Eisai looming once their drug Belviq clears DEA scheduling, VIVUS has launched the Save Now! program. In this video, health care analyst Max Macaluso discusses how this new program will impact VIVUS‘ business and how it might affect the competitive landscape of the obesity market.

Who will win the obesity drug market?
Can VIVUS pick up its lagging sales and fend off the competition, or will Arena Pharmaceuticals reign supreme in the obesity space? If you’re in the dark, grab copies of The Motley Fool’s premium research reports on VIVUS and Arena Pharmaceuticals to stay up to date. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market and reasons to buy and sell both stocks. Click now for an exclusive look at Arena and VIVUS — complete with a full year of free updates — today.

Editor’s note: This video was filmed on March 5, 2013.

The article Will This Obesity Biotech’s Latest Scheme Boost Sales? originally appeared on Fool.com.


Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");

function addEvent(obj, evType, fn, useCapture){
if (obj.addEventListener){
obj.addEventListener(evType, fn, useCapture);
return true;
} else if (obj.attachEvent){
var r = obj.attachEvent("on"+evType, fn);
return r;
}
}

addEvent(window, "load", function(){new FoolVisualSciences();})
addEvent(window, "load", function(){new PickAd();})

var themeName = 'dailyfinance.com';
var _gaq = _gaq || [];
_gaq.push(['_setAccount', 'UA-24928199-1']);
_gaq.push(['_trackPageview']);

(function () {

var ga = document.createElement('script');
ga.type = 'text/javascript';
ga.async = true;
ga.src = ('https:' == document.location.protocol ? 'https://ssl' : …read more
Source: FULL ARTICLE at DailyFinance

When Will This Obesity Drug Launch?

By Brian Orelli, The Motley Fool

Filed under:

Hurry up and wait.

That’s been the story of Arena Pharmaceuticals‘ Belviq. The obesity drug was approved back in June, but the biotech’s partner Eisai  couldn’t launch the drug because it had to wait for the Drug Enforcement Agency to determine how likely the drug is to be abused.

The DEA agreed with the Food and Drug Administration and recommended a Schedule IV designation. But more waiting ensued as the DEA took the standard 30-days of public comments.

The biotech held its fourth-quarter conference call Monday, but investors are still left waiting with no mention of an exact date for when Belviq will be launched. The public comment period ended in January, but the DEA is still reading the comments and hasn’t issued its final ruling.

Even after the final DEA ruling, investors could still be left waiting. Technically the DEA can ask for a 30-day waiting period after the final scheduling, although Eisai has asked for that to be waived.

How much the delay helps VIVUS‘ Qsymia is debatable. Sure, the biotech has gotten a few months free of competition from other new obesity treatments. But VIVUS may actually benefit from Eisai’s promotion to doctors, which need to be educated about the potential health benefits of taking obesity drugs. The drugs may not overlap much either; with its more severe side effect profile, Qsymia is likely to be prescribed to morbidly obese patients while Belviq finds a niche in patients that want a safer medication albeit with less weight loss.

You could argue that the third obesity drug player, Orexigen , benefits since it’s behind Arena, but probably not by much. The biotech hasn’t even resubmitted its application for Contrave. It could take six months after that to get approved. By that time, Qsymia and Belviq will be well into their launches; I doubt the delay will matter that much.

While you’re waiting for the launch to finally come, check out the Fool’s comprehensive look at Arena, including its massive opportunity, potential pitfalls, and key reasons to both buy and sell. To find out more about Arena — and get a full year of updates — click here to access your report today.

var FoolAnalyticsData = FoolAnalyticsData || []; FoolAnalyticsData.push({ eventType: “TickerReportPitch”, …read more
Source: FULL ARTICLE at DailyFinance

Mexican Billionaire Drug Kingpin "El Chapo" Guzman Named Chicago's Public Enemy No.1

By Dolia Estevez, Contributor

The world’s most powerful drug trafficker, Mexican billionaire Joaquin “El Chapo” Guzman Loera, was designated  by The Chicago Crime Commission and the DEA as Chicago’s Public Enemy #1,  a title held by Al Capone at the height of Prohibition in the 1930s.  In making the announcement on Valentines’ Day, Art Bilek, the commission’s executive vice president, said that  “What Al Capone was to beer and whiskey, Guzman is to narcotics.”  Guzman deserved the designation for the “viciousness, the evil and the power of this man.” …read more
Source: FULL ARTICLE at Forbes Latest

Mexican cartel kingpin named Chicago's new Public Enemy No. 1

Chicago’s new Public Enemy No. 1 is a cartel kingpin in Mexico.

It’s the first time the Chicago Crime Commission has used the label since Prohibition.

The commission and the Chicago office of the U.S. Drug Enforcement Administration will formally give Joaquin “El Chapo” Guzman that distinction Thursday.

The Public Enemy No. 1 label was created for mobster Al Capone. But the DEA says Sinaloa cartel leader Guzman is more menacing than the Chicago gangster was.

The DEA‘s top Chicago official, Jack Riley, says Guzman resides in a Mexican hideaway. But he says Guzman’s cartel is now the main narcotics supplier to Chicago and so is effectively a local crime boss.

Guzman has been indicted on federal trafficking charges in the nation’s third-largest city.

…read more
Source: FULL ARTICLE at Fox US News

Cartel kingpin Chicago's new Public Enemy No. 1

Chicago’s new Public Enemy No. 1 is a cartel kingpin in Mexico.

It’s the first time the Chicago Crime Commission has used the label since Prohibition.

The commission and the Chicago office of the U.S. Drug Enforcement Administration will formally give Joaquin “El Chapo” Guzman that distinction Thursday.

The Public Enemy No. 1 label was created for mobster Al Capone. But the DEA says Sinaloa cartel leader Guzman is more menacing than the Chicago gangster was.

The DEA‘s top Chicago official, Jack Riley, says Guzman resides in a Mexican hideaway. But he says Guzman’s cartel is now the main narcotics supplier to Chicago and so is effectively a local crime boss.

Guzman has been indicted on federal trafficking charges in the nation’s third-largest city.

…read more
Source: FULL ARTICLE at Fox US News

US military expands its billion dollar drug war in Latin America

The crew members aboard the USS Underwood could see through their night goggles what was happening on the fleeing go-fast boat: Someone was dumping bales.

When the Navy guided-missile frigate later dropped anchor in Panamanian waters on that sunny August morning, Ensign Clarissa Carpio, a 23-year-old from San Francisco, climbed into the inflatable dinghy with four unarmed sailors and two Coast Guard officers like herself, carrying light submachine guns. It was her first deployment, but Carpio was ready for combat.

Fighting drug traffickers was precisely what she’d trained for.

In the most expensive initiative in Latin America since the Cold War, the U.S. has militarized the battle against the traffickers, spending more than $20 billion in the past decade. U.S. Army troops, Air Force pilots and Navy ships outfitted with Coast Guard counternarcotics teams are routinely deployed to chase, track and capture drug smugglers.

The sophistication and violence of the traffickers is so great that the U.S. military is training not only law enforcement agents in Latin American nations, but their militaries as well, building a network of expensive hardware, radar, airplanes, ships, runways and refueling stations to stem the tide of illegal drugs from South America to the U.S.

According to State Department and Pentagon officials, stopping drug-trafficking organizations has become a matter of national security because they spread corruption, undermine fledgling democracies and can potentially finance terrorists.

U.S. drug czar Gil Kerlikowske, pointing to dramatic declines in violence and cocaine production in Colombia, says the strategy works.

“The results are historic and have tremendous implications, not just for the United States and the Western Hemisphere, but for the world,” he said at a conference on drug policy last year.

The Associated Press examined U.S. arms export authorizations, defense contracts, military aid, and exercises in the region, tracking a drug war strategy that began in Colombia, moved to Mexico and is now finding fresh focus in Central America, where brutal cartels mark an enemy motivated not by ideology but by cash.

The U.S. authorized the sale of a record $2.8 billion worth of guns, satellites, radar equipment and tear gas to Western Hemisphere nations in 2011, four times the authorized sales 10 years ago, according to the latest State Department reports.

Over the same decade, defense contracts jumped from $119 million to $629 million, supporting everything from Kevlar helmets for the Mexican army to airport runways in Aruba, according to federal contract data.

Last year $830 million, almost $9 out of every $10 of U.S. law enforcement and military aid spent in the region, went toward countering narcotics, up 30 percent in the past decade.

Many in the military and other law enforcement agencies — the Drug Enforcement Administration, U.S. Immigration and Customs Enforcement, FBI — applaud the U.S. strategy, but critics say militarizing the drug war in a region fraught with tender democracies and long-corrupt institutions can stir political instability while barely touching what the U.N. estimates is a $320 billion global illicit drug market.

Congressman Eliot Engel (D-N.Y.), who chaired the U.S. House Subcommittee on the Western Hemisphere for the past four years, says the U.S.-supported crackdown on Mexican cartels only left them “stronger and more violent.” He intends to reintroduce a proposal for a Western Hemisphere Drug Policy Commission to evaluate antinarcotics efforts.

“Billions upon billions of U.S. taxpayer dollars have been spent over the years to combat the drug trade in Latin America and the Caribbean,” he said. “In spite of our efforts, the positive results are few and far between.”

——

At any given moment, 4,000 U.S. troops are deployed in Latin America and as many as four U.S. Navy ships are plying the Caribbean and Pacific coastlines of Central America. U.S. pilots clocked more than 46,400 hours in 2011 flying anti-drug missions, and U.S. agents from at least 10 law enforcement agencies spread across the continent.

The U.S. trains thousands of Latin American troops, and employs its multibillion dollar radar equipment to gather intelligence to intercept traffickers and arrest cartel members.

These work in organized-crime networks that boast an estimated 11,000 flights annually and hundreds of boats and submersibles. They smuggle cocaine from the only place it’s produced, South America, to the land where it is most coveted, the United States.

One persistent problem is that in many of the partner nations, police are so institutionally weak or corrupt that governments have turned to their militaries to fight drug traffickers, often with violent results. Militaries are trained for combat, while police are trained to enforce laws.

“It is unfortunate that militaries have to be involved in what are essentially law enforcement engagements,” said Frank Mora, the outgoing deputy assistant secretary of defense for Western Hemisphere affairs. But he argues that many governments have little choice.

“We are not going to turn our backs on these governments or these institutions because they’ve found themselves in such a situation that they have to use their militaries in this way,” Mora said.

Mora said the effort is not tantamount to militarizing the war on drugs. He said the Defense Department‘s role is limited, by law, to monitoring and detection. Law enforcement agents, from the U.S. Coast Guard, Customs and Border Protection or other agencies are in charge of some of the busts, he said.

But the U.S. is deploying its own military. Not only is the Fourth Fleet in the Caribbean, the Pacific and the Atlantic, but the Marines were sent to Guatemala last year and the National Guard is in Honduras.

The Obama Administration sees these deployments as important missions with a worthy payoff. Hundreds of thousands of kilograms (pounds) of cocaine are seized en route to the U.S. every year, and the Defense Department estimates about 850 metric tons of cocaine departed South America last year toward the U.S., down 20 percent in just a year. The most recent U.S. survey found cocaine use fell significantly, from 2.4 million people in 2006 to 1.4 million in 2011.

Aboard the Underwood, the crew of 260 was clear on the mission. The ship’s bridge wings bear 16 cocaine “snowflakes” and two marijuana “leaves,” awarded to the Underwood by the Coast Guard command to be “proudly displayed” for its successful interdictions.

Standing on the bridge, Carpio’s team spotted its first bale of cocaine. And then, after 2 1/2 weeks plying the Caribbean in search of drug traffickers, they spotted another, and then many more.

“In all we found 49 bales,” Carpio said in an interview aboard the ship. “It was very impressive to see the bales popping along the water in a row.”

Wrapped in black and white tarp, they were so heavy she could barely pull one out of the water. Later, officials said they’d collected $27 million worth of cocaine.

——

The current U.S. strategy began in Colombia in 2000, with an eight-year effort that cost more than $7 billion to stop the flow from the world’s top cocaine producer. During Plan Colombia, the national police force, working closely with dozens of DEA agents, successfully locked up top drug traffickers.

But then came “the balloon effect.”

As a result of Plan Colombia‘s pressure, traffickers were forced to find new coca-growing lands in Peru and Bolivia, and trafficking routes shifted as well from Florida to the U.S.-Mexico border.

Thus a $1.6 billion, 4-year Merida Initiative was launched in 2008. Once more, drug kingpins were caught or killed, and as cartels fought to control trafficking routes, increasingly gruesome killings topped 70,000 in six years.

Mexican cartel bosses, feeling the squeeze, turned to Central America as the first stop for South American cocaine, attracted by weaker governments and corrupt authorities.

“Now, all of a sudden, the tide has turned,” said Brick Scoggins, who manages the Defense Department‘s counter-narcotics programs in most of Latin America and the Caribbean. “I’d say northern tier countries of El Salvador, Honduras, Guatemala and Belize have become a key focus area.”

The latest iteration is the $165 million Central America Regional Security Initiative, which includes Operation Martillo (Hammer), a year-old U.S.-led mission. The operation has no end date and is focused on the seas off Central America‘s beach-lined coasts, key shipping routes for 90 percent of the estimated 850 metric tons of cocaine headed to the U.S.

As part of Operation Martillo, 200 U.S. Marines began patrolling Guatemala‘s western coast in August, their helicopters soaring above villages at night as they headed out to sea to find “narco-submarines” and shiploads of drugs. The troops also brought millions of dollars’ worth of computers and intelligence-gathering technology to analyze communications between suspected drug dealers.

Assistant Secretary of State William Brownfield, head of the Bureau of International Narcotics and Law Enforcement Affairs, predicts the balloon effect will play out in Central America before moving to the Caribbean.

The goal, he said, is to make it so hard for traffickers to move drugs to the U.S. that they will eventually opt out of North America, where cocaine use is falling. Traffickers would likely look for easier, more expanding markets, shifting sales to a growing customer base in Europe, Africa and elsewhere in the world.

Brownfield said almost all Peruvian and Bolivian cocaine goes east through Brazil and Argentina and then to Western Europe. Cocaine that reaches North America mostly comes from Colombia, he said, with U.S. figures showing production falling sharply, from 700 metric tons in 2001 to 195 metric tons today — though estimates vary widely.

When the drug war turns bloody, he said, the strategy is working.

“The bloodshed tends to occur and increase when these trafficking organizations, which are large, powerful, rich, extremely violent and potentially bloody, … come under some degree of pressure,” he said.

Yet the strategy has often backfired when foreign partners proved too inexperienced to fight drug traffickers or so corrupt they switched sides.

In Mexico, for example, the U.S. focused on improving the professionalism of the federal police. But the effort’s success was openly questioned after federal police at Mexico City’s Benito Juarez International Airport opened fire at each other, killing three.

In August critics were even more concerned when two CIA officers riding in a U.S. Embassy SUV were ambushed by Mexican federal police allegedly working for an organized crime group. The police riddled the armored SUV with 152 bullets, wounding both officers.

The new strategy in Honduras has had its own fits and starts.

Last year, the U.S. Defense Department spent a record $67.4 million on military contracts in Honduras, triple the 2002 defense contracts there well above the $45.6 million spent in neighboring Guatemala in 2012. The U.S. also spent about $2 million training more than 300 Honduran military personnel in 2011, and $89 million in annual spending to maintain Joint Task Force Bravo, a 600-member U.S. unit based at Soto Cano Air Base.

Further, neither the State Department nor the Pentagon could provide details explaining a 2011 $1.3 billion authorization for exports of military electronics to Honduras — although that would amount to almost half of all U.S. arms exports for the entire Western Hemisphere.

In May, on the other side of the country, Honduran national police rappelled from U.S. helicopters to bust drug traffickers near the remote village of Ahuas, killing four allegedly innocent civilians and scattering locals who were loading some 450 kilograms (close to 1,000 pounds) of cocaine into a boat.

The incident drew international attention and demands for an investigation when the DEA confirmed it had agents aboard the helicopters advising their Honduran counterparts. Villagers spoke of English-speaking commandos kicking in doors and handcuffing locals just after the shooting, searching for drug traffickers.

Six weeks later, townspeople watched in shock as laborers exhumed the first of four muddy graves. At each burial site, workers pulled out the decomposing bodies of two women and two young men, and laid them on tarps.

Forensic scientists conducted their graveside autopsies in the open air, probing for bullet wounds and searching for signs the women had been pregnant, as villagers had claimed.

Government investigators concluded there was no wrongdoing in the raid. In the subsequent months, DEA agents shot and killed suspects they said threatened them in two separate incidents, and the U.S. temporarily suspended the sharing of radar intelligence because the Central American nation’s air force shot down two suspected drug planes, a violation of rules of engagement. Support was also withheld for the national police after it was learned that its new director had been tied to death squads.

As the new year begins, Congress is still withholding an estimated $30 million in aid to Honduras, about a third of all the U.S. aid slotted for this year.

But there are no plans to rethink the strategy.

Scoggins, the Defense Department‘s counter-narcotics manager, said operations in Central America are expected to grow for the next five years.

“It’s not for me to say if it’s the correct strategy. It’s the strategy we are using,” said Scoggins. “I don’t know what the alternative is.”

Source: FULL ARTICLE at Fox US News

AP Exclusive: New HQ bids to end agency rivalry

A first-of-its-kind headquarters has opened in Chicago for 70 federal agents, police and prosecutors to work side-by-side, year-round to fight drug traffickers — a set-up meant to end inter-agency rivalry and miscommunication that can hamper investigations.

The recent, fanfare-free opening of the Chicago Strike Force building comes as Mexican cartels now supply over 90 percent of the narcotics in Chicago, and as street gangs vying for turf to sell those drugs kill each other and bystanders caught in the crossfire.

Inter-agency and -department cooperation is hardly a novel concept, but typically takes the form of occasional meetings or temporary joint task forces on specific investigations, said Jack Riley, the head of Chicago’s DEA office.

“But you can’t talk to your counterparts in once-a-week meetings — you have to talk as things are happening,” said Riley, who took the lead in pushing for the facility. “When we get information here, it’s not put in a pile and forgotten. It’s acted on, now.”

Riley gave The Associated Press an exclusive tour of the three-story brick building. Citing security, he asked the AP not to reveal its exact location.

The staff includes city and suburban police, as well as agents from the DEA, FBI, Immigration and Customs Enforcement, the IRS and a half-dozen other agencies. In another rarity, U.S. and state prosecutors also work alongside one another. Riley declined to reveal its budget.

It’ll take time to see if the headquarters makes anti-trafficking efforts in Chicago more efficient, said Fred Burton, a security analyst for the global intelligence firm Stratfor.

“It sounds great on paper,” he said. “But getting federal agencies to act in unison can be like herding cats.”

Over the years, competition has led to situations where agencies end up unknowingly targeting the same traffickers, creating the risk that they could inadvertently foil each other’s investigations, Riley said.

Thus, the headquarters was designed to foster camaraderie. Employees’ desks all sit in a warehouse-sized room with no dividers or signs identifying who belongs to what agency. Response teams are comprised of members from each agency.

A major focus of their investigations will be the point of contact between major traffickers and local gangs, who serve as street-level salesmen. That’s when traffickers are especially vulnerable, Reilly says, because they meet at unfamiliar places or use phones that can be wiretapped.

The ultimate goal is to arrest suspects, squeeze them to cooperate and then move along the cartel’s chain of command to indict everyone from the street dealer to the kingpins in Mexico. They hope to replicate investigations like one that led to the 2009 indictment of key leaders of the Sinaloa cartel and the extradition of Sinaloa lieutenant Vicente Zambada, who’ll stand trial in Chicago this year.

Beat officers should also benefit from the new headquarters, Riley said. A single office with a range of experts on everything from which gang controls what block to cartel structures in Mexico should help officers in the field make sense of anything suspicious, he said.

“They can call and say, ‘Hey, I saw this guy who I think is a gang member hand a bag to this other guy. Does it mean anything? “‘ he said. “Before, there really wasn’t a good place to call. There is now.”

___

Follow Michael Tarm at www.twitter.com/mtarm

Source: FULL ARTICLE at Fox US News

Hash oil causes blast, hurts 3 near SeaWorld in SD

An explosion tore through a hotel near SeaWorld San Diego where a couple was allegedly extracting hash oil, sending guests fleeing for safety and putting three people in the hospital, authorities said.

A 22-year-old man in the room suffered life-threatening injuries in the Wednesday explosion at the three-story Heritage Inn Sea World Hotel, authorities said. Also hurt were a woman in the room and a young man staying next door.

Julie Jordan of San Diego was sleeping with a friend’s baby in a nearby room when she felt the building shake violently, then heard a loud explosion. She ran outside and saw a shattered window and a badly injured man sitting at the bottom of some stairs, she said.

“There was chaos. I was very confused. When I came out of the room, I didn’t know which way to turn,” she said.

Another guest, Joseph Tydingco, said “It was like a disaster zone in there.”

Investigators found several boxes containing canisters of butane inside the room where the blast occurred, police Lt. Joseph Ramos said.

The butane apparently was ignited by a cigarette, Fire-Rescue Department spokesman Maurice Luque said. The second-floor room looked like a “war zone,” he said.

“It was a very intense and devastating explosion,” Luque said.

Hash oil is made by packing finely ground stems and leaves of marijuana plants in a pipe and pouring butane through it, said Amy Roderick, a spokeswoman for the U.S. Drug Enforcement Administration, which is leading the investigation. The liquid typically is then cooked on a stove to separate the butane.

Hash oil averages about 15 percent THC, the chief intoxicant in marijuana, according to the DEA. A drop or two is about as potent as a marijuana cigarette.

The DEA did not confirm that a cigarette ignited the butane or know the size of the drug operation.

“It just looks like a bomb that blew up there,” Roderick said. “It’s hard for us to tell what was going on there.”

The DEA will review the evidence before deciding whether to send the case to the San Diego County district attorney’s office for criminal charges.

Authorities said the couple in the room where the explosion occurred suffered burns, and the man in the neighboring room had bruises, cuts and possible burns.

The badly burned man was in “very, very serious” condition, Luque said. His female companion and the man in the next room — both believed to be around 20 years old — were in moderate condition. Their names were not released.

Joseph Tydingco, 52, rushed out of his room after what felt like a major earthquake and saw black smoke billowing from rooms. He grabbed a fire extinguisher and, with another guest, removed mattresses as they heard people screaming outside.

Tydingco, a SeaWorld maintenance worker, estimated that walls collapsed in six rooms. Police said at least four rooms were destroyed or badly damaged.

The blaze was mostly under control within minutes of the blast, which happened at about 11:15 a.m.

Tydingco said the hotel largely caters to vacationing families on tight budgets and local residents who lack enough cash to sign a rental lease.

Source: FULL ARTICLE at Fox US News

DEA Agents Got Prostitute for Secret Service Agent: Probe

By Matt Cantor The Drug Enforcement Administration’s alleged role in the Secret Service prostitution scandal deepens. A pair of DEA agents set up a liaison between a Secret Service Agent and a prostitute in Colombia in April 2012, a Justice department probe finds. Another DEA agent wasn’t involved in that particular episode, but…
Source: FULL ARTICLE at Newser – Home